Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Wednesday

Galectin Therapeutics (NASDAQ:GALT) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Galectin Therapeutics Trading Down 5.0%

GALT opened at $1.32 on Wednesday. The firm has a market capitalization of $83.40 million, a PE ratio of -1.81 and a beta of 0.62. Galectin Therapeutics has a twelve month low of $0.73 and a twelve month high of $3.28. The firm’s 50-day moving average price is $1.43 and its 200 day moving average price is $1.67.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of Galectin Therapeutics in a research report on Wednesday, April 2nd.

Hedge Funds Weigh In On Galectin Therapeutics

An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE raised its position in Galectin Therapeutics Inc. (NASDAQ:GALT) by 101.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,358 shares of the company’s stock after purchasing an additional 19,316 shares during the quarter. Bank of America Corp DE owned about 0.06% of Galectin Therapeutics worth $49,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.